Skip to main content
Premium Trial:

Request an Annual Quote

Patterson s Post-Celera Proteomics Digs, Lion Hires New Software Development Chief, and Others

NEW YORK, Jan. 22-Geneva Bioinformatics appointed Nasri Nahas as chief executive officer, the company announced today.

 

Nahas was previously chief operating officer. He joined the company in 2001.

 

Prior to that, he worked with Genset and ValiGen.

 


 

Myriad Genetics hired Jerry Lanchbury as senior vice president of research and development, the company said today.

 

He will oversee all non-pharmaceutical R&D at the company.

 

Lanchbury was previously head of the Molecular Immunogenetics Unit at the King's College GKT School of Medicine. He has a doctorate in population genetics, and has developed techniques for investigating the genetic basis of complex disease.

 

Myriad Genetics  is based in Salt Lake City.

 


 

NeoGenesis Pharmaceuticals appointed Arthur Patchett to its scientific advisory board, the company said on Jan. 21.

 

Patchett was a vice president of medicinal chemistry at Merck Research Laboratories until his retirement in 2000.

 

He has co-authored more than 170 papers and more than 180 patents.

 

NeoGenesis, based in Cambridge, Mass., uses an automated ligand identification system to find small molecules.

 

 


 

Ardais has appointed Gregory Phelps as president and chief executive officer, the clinical genomics company said on Jan. 20.

 

He was previously vice chairman of Dyax Corporation, where he led corporate development. He will remain a director of that company.

 

He replaces Eric Gordon, who is no longer with the company.

 

Prior to that, Phelps was executive vice president of Genzyme, and has also served as chief executive officer of Viagene and of Zymogenetics.

 

Ardais, based in Lexington, Mass., has amassed a repository of more than 130,000 tissue samples with linked clinical data.

 


Former Celera proteomics chief Scott Patterson joined Farmal Biomedicines as chief scientific officer this week.

 

The Pasadena, Calif.-based company has yet to make its formal public debut, but Patterson told GenomeWeb that it will be involved in the discovery and development of protein therapeutics. Research will focus on oncology, among other areas.

 

Patterson joined Celera as senior director of proteomics in November 2000. He was previously at Amgen.

 


 

IBM's Reiner Doelle has been hired as vice president for global software development at Lion Bioscience, the company said on Jan. 16. 

 

Doelle's job is to improve productivity and quality control in the company's software development. The position is newly created.

 

He previously held positions in marketing and sales for IBM in the U.S. and Germany.

 


 

Xantos Biomedicine has hired Ulrich Brinkmann as chief scientific officer, the company said on Jan. 16.

 

He was previously chief scientific officer of Epidauros Biotechnology, a German pharmacogenetics firm, and worked with the National Cancer Institute's Ira Pastan, who is developing new treatments for metastatic cancer.

 

He replaces Christoph Hergersberg.

 

Xantos, based in Munich, is a functional genomics company looking for genes associated with disease.

 


 

Protedyne Corporation said on Jan. 17 that it had hired scientific advisory board member as Ralph Ito as senior scientific director. Ito will oversee the company's laboratory services division and direct its research initiatives.

 

He was previously vice president and director of laboratory services for Zoion, which provides human tissue for drug target discovery.

 

Protedyne is based in Windsor, Conn.

 


 

Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

 

 

 

 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more